Short-term and divergent regulation of FGF-19 and FGF-21 during oral lipid tolerance test but not oral glucose tolerance test

Experimental and Clinical Endocrinology and Diabetes

Volumn 123, Issue 2, 2015, Pages 88-94

  Schmid, A ^a   Leszczak, S ^b   Ober, I ^b   Karrasch, T ^a   Schaffler A ^a  

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

FGF 19; FGF 21; glucose tolerance test; lipid tolerance test

Indexed keywords

CARBOHYDRATE; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR 21; GLUCOSE; TRIACYLGLYCEROL; CARBOHYDRATE DIET; FAT INTAKE; FGF19 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR;

ADULT; ANTHROPOMETRY; ARTICLE; CARBOHYDRATE DIET; ENZYME LINKED IMMUNOSORBENT ASSAY; FAT INTAKE; FAT TOLERANCE TEST; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; MALE; NEGATIVE FEEDBACK; NORMAL HUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WAIST HIP RATIO; ADOLESCENT; BLOOD; GLUCOSE TOLERANCE TEST; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; DIETARY CARBOHYDRATES; DIETARY FATS; FEMALE; FIBROBLAST GROWTH FACTORS; GLUCOSE TOLERANCE TEST; HUMANS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84923351468     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0034-1395635     Document Type: Article

References (22)

1. Koerner A., Kratzsch J., Kiess W. Adipocytokines: leptin - the classical, resistin - the controversial, adiponectin - the promising, and more to come. Best Pract Res Clin Endocrinol Metab: 2005; 19 525 546
2. Flehmig G., Scholz M., Kloting N. et al. Identification of adipokine clusters related to parameters of fat mass, insulin sensitivity and inflammation. PloS one: 2014; 9 e99785
3. Wu X., Ge H., Baribault H. et al. Dual actions of fibroblast growth factor 19 on lipid metabolism. Journal of lipid research: 2013; 54 325 332
4. Bhatnagar S., Damron H. A., Hillgartner F. B. Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis. The Journal of biological chemistry: 2009; 284 10023 10033
5. Iglesias P., Selgas R., Romero S. et al. Biological role, clinical significance, and therapeutic possibilities of the recently discovered metabolic hormone fibroblastic growth factor 21. Eur J Endocrinol: 2012; 167 301 309
6. Kharitonenkov A., Dunbar J. D., Bina H. A. et al. FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho. J Cell Physiol: 2008; 215 1 7
7. Miyata M., Hata T., Yamazoe Y. et al. SREBP-2 negatively regulates FXR-dependent transcription of FGF19 in human intestinal cells. Biochem Biophys Res Commun: 2014; 443 477 482
8. Hofmann A. F. Biliary secretion and excretion in health and disease: current concepts. Annals of hepatology: 2007; 6 15 27
9. Lindegaard B., Hvid T., Grondahl T. et al. Expression of fibroblast growth factor-21 in muscle is associated with lipodystrophy, insulin resistance and lipid disturbances in patients with HIV. PloS one: 2013; 8 e55632
10. Bobbert T., Schwarz F., Fischer-Rosinsky A. et al. Fibroblast growth factor 21 predicts the metabolic syndrome and type 2 diabetes in Caucasians. Diabetes Care: 2013; 36 145 149
11. Bala M., Martin J., Kopp A. et al. In vivo suppression of visfatin by oral glucose uptake: evidence for a novel incretin-like effect by glucagon-like peptide-1 (GLP-1). J Clin Endocrinol Metab: 2011; 96 2493 2501
12. Karrasch T., Leszczak S., Bala M. et al. Short-term regulation of Visfatin release in vivo by oral lipid ingestion and in vitro by fatty acid stimulation. Exp Clin Endocrinol Diabetes: 2014; 122 126 134
13. Stejskal D., Karpisek M., Hanulova Z. et al. Fibroblast growth factor-19: development, analytical characterization and clinical evaluation of a new ELISA test. Scandinavian journal of clinical and laboratory investigation: 2008; 68 501 507
14. Li M., Qureshi A. R., Ellis E. et al. Impaired postprandial fibroblast growth factor (FGF)-19 response in patients with stage 5 chronic kidney diseases is ameliorated following antioxidative therapy. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association: 2013; 28 04 iv212 iv219
15. Barutcuoglu B., Basol G., Cakir Y. et al. Fibroblast growth factor-19 levels in type 2 diabetic patients with metabolic syndrome. Annals of clinical and laboratory science: 2011; 41 390 396
16. Giannini C., Feldstein A. E., Santoro N. et al. Circulating levels of FGF-21 in obese youth: associations with liver fat content and markers of liver damage. J Clin Endocrinol Metab: 2013; 98 2993 3000
17. Haluzikova D., Lacinova Z., Kavalkova P. et al. Laparoscopic sleeve gastrectomy differentially affects serum concentrations of FGF-19 and FGF-21 in morbidly obese subjects. Obesity: 2013; 21 1335 1342
18. Chavez A. O., Molina-Carrion M., Abdul-Ghani M. A. et al. Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care: 2009; 32 1542 1546
19. Li H., Bao Y., Xu A. et al. Serum fibroblast growth factor 21 is associated with adverse lipid profiles and gamma-glutamyltransferase but not insulin sensitivity in Chinese subjects. J Clin Endocrinol Metab: 2009; 94 2151 2156
20. Tyynismaa H., Raivio T., Hakkarainen A. et al. Liver fat but not other adiposity measures influence circulating FGF21 levels in healthy young adult twins. J Clin Endocrinol Metab: 2011; 96 E351 E355
21. Bisgaard A., Sorensen K., Johannsen T. H. et al. Significant gender difference in serum levels of fibroblast growth factor 21 in Danish children and adolescents. International journal of pediatric endocrinology: 2014; 2014 7
22. Matikainen N., Taskinen M. R., Stennabb S. et al. Decrease in circulating fibroblast growth factor 21 after an oral fat load is related to postprandial triglyceride-rich lipoproteins and liver fat. Eur J Endocrinol: 2012; 166 487 492